Seagen and remegen announce exclusive worldwide license and co-development agreement for disitamab vedotin

Bothell, wash. & yantai, china--(business wire)--seagen inc. (nasdaq: sgen), a world leader and pioneer in antibody-drug conjugate (adc) therapies, and remegen co., ltd. (9995.hk), a leading innovative biopharmaceutical company in china, today announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel her2-targeted adc. disitamab vedotin combines the drug-linker technology originally developed by seagen w
SGEN Ratings Summary
SGEN Quant Ranking